---
title: "Acusensus grows revenue 40% but swings to deeper half-year loss on legal settlement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276948667.md"
description: "Acusensus Ltd reported a 40% increase in half-year revenue to $40.3 million, driven by new contracts and growth in the U.S. market. However, the company faced a net loss of $20.8 million due to high operating costs and a $16 million legal settlement. Despite the loss, net tangible assets per share rose to $0.33, and no dividend was declared. Analysts rate the stock as a Buy with a price target of A$2.30, reflecting confidence in the company's growth strategy despite near-term margin pressures."
datetime: "2026-02-25T22:15:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276948667.md)
  - [en](https://longbridge.com/en/news/276948667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276948667.md)
---

# Acusensus grows revenue 40% but swings to deeper half-year loss on legal settlement

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An announcement from Acusensus Ltd ( (AU:ACE) ) is now available.

Acusensus reported a 40% increase in half-year revenue to $40.3 million for the period ended 31 December 2025, driven by new enforcement contracts in New Zealand and Western Australia, higher unit deployments in Queensland and continued growth in the U.S. market. Despite the strong top-line performance, the company booked a net loss after tax of $20.8 million as higher operating costs to support expansion, strategic growth investments and $16 million in litigation settlement expenses weighed on profitability, while net tangible assets per share edged up to $0.33 and no dividend was declared for the period.

The inclusion of the Redflex Traffic Systems settlement within the latest half-year reflects a deliberate move to clear legacy legal overhangs in line with accounting standards and may help reduce uncertainty for investors in future periods. However, the expanded loss underlines the near-term margin pressures associated with Acusensus’ growth strategy, as the company balances international expansion and contract wins against the cost and risk profile of scaling its enforcement technology platforms.

The most recent analyst rating on (AU:ACE) stock is a Buy with a A$2.30 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.

**More about Acusensus Ltd**

Acusensus Limited is a traffic enforcement technology company that provides automated solutions such as mobile speed, multi-function trailer and distracted driving detection systems. The business operates across Australia, New Zealand, the U.S. and the U.K., with a growing presence in North America and inflation-linked revenues from selected long-term contracts.

**Average Trading Volume:** 160,481

**Technical Sentiment Signal:** Buy

**Current Market Cap:** A$271.1M

See more data about ACE stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [ASXC.US](https://longbridge.com/en/quote/ASXC.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business](https://longbridge.com/en/news/286889480.md)
- [Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal](https://longbridge.com/en/news/286808399.md)
- [Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain | MDT Stock News](https://longbridge.com/en/news/287072903.md)
- [Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results](https://longbridge.com/en/news/286942821.md)